Gastroduodenal tolerability of nabumetone versus naproxen in the treatment of rheumatic patients.

摘要: Objective : The objective of this endoscopic, double-blind study was to evaluate the gastric tolerability nabumetone, a novel nonsteroidal anti-inflammatory drug, compared with naproxen in patients rheumatoid arthritis. Methods Patients definite or classic arthritis as defined by ACR criteria were eligible for entry into if an initial endoscopy normal showed presence only one erosion two submucosal hemorrhages. After 7-day washout period, randomized receive either 1 g, naproxen, 500 mg, b.i.d. Blinding achieved use double dummies. Endoscopy repeated after 4 wk treatment. primary efficacy parameters Ritchie articular index, duration morning stiffness, and global assessments. Results Gastric mucosal lesions different degrees observed 9% (2/22) nabumetone-treated 40% (12/30) those who received (p = 0.01). One duodenal ulcer found patient treated had history ulcer. In group, six have Clinical evaluation rheumatological symptomatology no statistical difference relieving symptoms between drugs However, dropped out because lack efficacy, group. Side effects noted three nabumetone 14 0.004). Conclusion This that g daily, results significantly less deterioration mucosa than mg but appears be more g.